Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer PatientsKimberly R. Kalli, Keith L. Knutson, Matthew S. Block et al.|Clinical Cancer Research|2018Cited by 97
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trialMatthew S. Block, Akseli Hemminki|Nature Communications|2025Cited by 26
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J. Hieken, Matthew S. Block|Nature Communications|2024Cited by 25
Comparison of replicating and nonreplicating vaccines against SARS-CoV-2Haley Mudrick, Shane Massey, Erin B. McGlinch et al.|Science Advances|2022Cited by 16
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Clinical Cancer Research|2024Cited by 15